Cytokinetics Announces Board and Executive Changes

Ticker: CYTK · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1061983

Cytokinetics Inc 8-K Filing Summary
FieldDetail
CompanyCytokinetics Inc (CYTK)
Form Type8-K
Filed DateDec 16, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

Related Tickers: CYTK

TL;DR

Cytokinetics filed an 8-K on 12/16/24 for board/exec changes. Details TBD.

AI Summary

On December 16, 2024, Cytokinetics, Incorporated filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on dollar amounts or new appointments are not provided in this excerpt.

Why It Matters

Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or future performance expectations.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may impact future company performance and strategy.

Key Numbers

  • 000-50633 — SEC File Number (Identifies Cytokinetics' filings with the SEC.)
  • 94-3291317 — IRS Employer Identification No. (Tax identification number for Cytokinetics.)

Key Players & Entities

  • Cytokinetics, Incorporated (company) — Registrant
  • Delaware (jurisdiction) — State of Incorporation
  • South San Francisco, California (location) — Principal Executive Offices

FAQ

What specific changes were made to the board of directors?

The filing indicates the election of directors, but the specific names and number of directors elected are not detailed in this excerpt.

Are there any new executive officers appointed?

The filing mentions 'Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers,' suggesting potential changes, but does not name specific individuals or roles.

What is the date of the earliest event reported in this 8-K?

The earliest event reported is December 16, 2024.

What is Cytokinetics' principal executive office address?

Cytokinetics' principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California, 94080.

What is the SIC code for Cytokinetics?

The Standard Industrial Classification (SIC) code for Cytokinetics is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-16 16:38:08

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: December 16, 2024 By: /s/ John O. Faurescu John O. Faurescu, Vice President, Associate General Counsel & Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.